PE20040175A1 - Metodo para tratar enfermedades o condiciones desmielinizantes - Google Patents

Metodo para tratar enfermedades o condiciones desmielinizantes

Info

Publication number
PE20040175A1
PE20040175A1 PE2002000159A PE2002000159A PE20040175A1 PE 20040175 A1 PE20040175 A1 PE 20040175A1 PE 2002000159 A PE2002000159 A PE 2002000159A PE 2002000159 A PE2002000159 A PE 2002000159A PE 20040175 A1 PE20040175 A1 PE 20040175A1
Authority
PE
Peru
Prior art keywords
alkyl
alkylene
halogen
hydroxy
alcoxy
Prior art date
Application number
PE2002000159A
Other languages
English (en)
Inventor
Craig P Smith
Michel P Rathbone
Margaret Petty
David Rampe
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of PE20040175A1 publication Critical patent/PE20040175A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

SE REFIERE A UN METODO PARA TRATAR ENFERMEDADES DE DESMIELINACION TALES COMO ESCLEROSIS MULTIPLE, LESION EN LA MEDULA ESPINAL, INFARTO, LESION TRAUMATICA CEREBRAL QUE COMPRENDE ADMINISTRAR UN BLOQUEADOR DEL CANAL DE POTASIO COMO N-(PIRIDIL)-1H-INDOL-1-AMINAS DE FORMULA I; DONDE m Y n SON 0,1,2; p ES 0-1; R ES H, HALOGENO, TRIFLUOROMETILO, ALQUILO C1-C6, ALCOXI C1-C6, BENCILOXI, HIDROXI, NITRO, AMINO; R1 ES H, ALQUILO C1-C6, ALQUENILO C1-C6, ALCANOIL C1-C6, HALOGENO, CIANO, ALQUILO C1-C6-CO, CN-ALQUILENO C1-C6, NR'R"-ALQUILENO C1-C6; R' Y R" SON H, ALQUILO C1-C6, -OCO-ALQUILENO C1-C6, ALQUILO C1-C6, -CH(OH)R4; R4 ES H, ALQUILO C1-C6; R2 ES H, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON HALOGENO, HIDROXI, BENCILOXI, ALQUENILO C1-C6, ALQUINILO C1-C6, ENTRE OTROS; R3 ES H, NITRO, AMINO, HALOGENO, ALCOXI C1-C6, HIDROXI, ALQUILO C1-C6. UN COMPUESTO PREFERIDO ES: N-(3-FLUORO-4-PIRIDIL)-N-PROPIL-3-METIL-1H-INDOL-1-AMINA,ENTRE OTROS.LOS COMPUESTOS PUEDEN SER UTILES PARA LA REHABILITACION DE LA APOPLEJIA, EL TRATAMIENTO DE LA IRRITACION Y DISFUNCION DE LA VEJIGA Y DEL DOLOR NEUROPATICO O DOLOR INDUCIDO POR QUIMIOCINA
PE2002000159A 2001-02-15 2002-02-26 Metodo para tratar enfermedades o condiciones desmielinizantes PE20040175A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15

Publications (1)

Publication Number Publication Date
PE20040175A1 true PE20040175A1 (es) 2004-03-29

Family

ID=23024747

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000159A PE20040175A1 (es) 2001-02-15 2002-02-26 Metodo para tratar enfermedades o condiciones desmielinizantes

Country Status (39)

Country Link
US (10) US6967210B2 (es)
EP (1) EP1368031A2 (es)
JP (3) JP2004518711A (es)
KR (3) KR100951540B1 (es)
CN (2) CN1529598A (es)
AP (1) AP1749A (es)
AR (1) AR035750A1 (es)
AU (3) AU2002247200B9 (es)
BR (1) BR0207272A (es)
CA (1) CA2438712A1 (es)
CO (1) CO5390085A1 (es)
CR (1) CR7023A (es)
CZ (1) CZ20032172A3 (es)
EA (2) EA012409B1 (es)
EC (1) ECSP024218A (es)
EE (1) EE200300363A (es)
GB (1) GB0119435D0 (es)
HK (1) HK1080361B (es)
HR (1) HRP20030652A2 (es)
HU (1) HUP0303203A3 (es)
IL (2) IL157341A0 (es)
MA (1) MA26152A1 (es)
ME (1) MEP21208A (es)
MX (1) MXPA03006110A (es)
MY (1) MY157745A (es)
NO (1) NO20033622L (es)
NZ (4) NZ539159A (es)
OA (1) OA12549A (es)
PA (1) PA8540101A1 (es)
PE (1) PE20040175A1 (es)
PL (1) PL363638A1 (es)
SG (1) SG134170A1 (es)
SK (1) SK10392003A3 (es)
TR (4) TR200800691T2 (es)
TW (1) TWI325319B (es)
UA (2) UA80394C2 (es)
WO (1) WO2002064126A2 (es)
YU (1) YU62903A (es)
ZA (1) ZA200306124B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
WO2004058168A2 (en) * 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
US20040209960A1 (en) * 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
BRPI0408608A (pt) * 2003-03-21 2006-03-07 Dynogen Pharmaceuticals Inc uso de moduladores da subunidade (alfa)2(delta) de canal de cálcio e moduladores de músculo liso para tratamento de sintoma de um distúrbio do trato urinário inferior
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
CN102822979B (zh) * 2010-03-26 2015-08-26 株式会社半导体能源研究所 半导体器件
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
US20130030025A1 (en) * 2011-01-28 2013-01-31 Wessel Thomas C Use of potassium channel blockers to treat cerebral palsy
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2019126643A1 (en) * 2017-12-22 2019-06-27 Massachusetts Institute Of Technology Compositions and methods for williams syndrome (ws) therapy
CA3207205A1 (en) * 2021-01-20 2022-07-28 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
DE3852335T2 (de) * 1987-04-24 1995-05-11 Hoechst Roussel Pharma N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel.
US4970218A (en) 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
ES2068294T3 (es) * 1989-08-02 1995-04-16 Hoechst Roussel Pharma 2,3-dihidro-1-(piridinilamino)-indoles, un procedimiento para su preparacion y su uso como medicamentos.
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
US5939405A (en) * 1998-01-29 1999-08-17 Bristol-Myers Squibb Company Phosphate derivatives of diaryl 1,3,4-oxadiazolone
AU5483500A (en) * 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
US20060025452A1 (en) 2006-02-02
YU62903A (sh) 2006-05-25
EA200300882A1 (ru) 2003-12-25
KR20090005254A (ko) 2009-01-12
HRP20030652A2 (en) 2005-06-30
PA8540101A1 (es) 2003-09-05
WO2002064126A2 (en) 2002-08-22
HUP0303203A3 (en) 2007-11-28
WO2002064126A3 (en) 2003-02-20
US7230015B2 (en) 2007-06-12
SG134170A1 (en) 2007-08-29
UA88773C2 (ru) 2009-11-25
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
MXPA03006110A (es) 2005-07-01
US20090270458A1 (en) 2009-10-29
EA200600896A1 (ru) 2006-08-25
HUP0303203A2 (hu) 2003-12-29
KR100951542B1 (ko) 2010-04-09
CN100522164C (zh) 2009-08-05
AU2009238332A1 (en) 2009-12-10
TR200800693T2 (tr) 2008-07-21
CZ20032172A3 (cs) 2004-01-14
EE200300363A (et) 2003-10-15
KR100951540B1 (ko) 2010-04-09
US20090209595A1 (en) 2009-08-20
IL157341A0 (en) 2004-02-19
AU2002247200B2 (en) 2007-12-13
BR0207272A (pt) 2004-02-10
CN1679564A (zh) 2005-10-12
EP1368031A2 (en) 2003-12-10
AP2003002834A0 (en) 2003-09-30
CO5390085A1 (es) 2004-04-30
ECSP024218A (es) 2003-09-24
CA2438712A1 (en) 2002-08-22
US20040157888A1 (en) 2004-08-12
MEP21208A (en) 2010-06-10
CN1529598A (zh) 2004-09-15
KR20090005255A (ko) 2009-01-12
TR200301330T2 (tr) 2004-12-21
US20050159456A1 (en) 2005-07-21
MA26152A1 (fr) 2004-07-01
NZ556697A (en) 2009-01-31
US20040157889A1 (en) 2004-08-12
US20090281147A1 (en) 2009-11-12
AU2008201179A1 (en) 2008-04-03
NZ527011A (en) 2005-07-29
US20090209594A1 (en) 2009-08-20
JP2010120958A (ja) 2010-06-03
US20030105150A1 (en) 2003-06-05
NO20033622D0 (no) 2003-08-14
ZA200306124B (en) 2004-11-08
HK1080361B (zh) 2009-10-30
NZ539159A (en) 2006-11-30
JP2009185045A (ja) 2009-08-20
US7534803B2 (en) 2009-05-19
AU2002247200B9 (en) 2008-07-10
US6967210B2 (en) 2005-11-22
AU2008201179B2 (en) 2009-08-20
OA12549A (en) 2006-06-05
KR20040014459A (ko) 2004-02-14
PL363638A1 (en) 2004-11-29
EA012409B1 (ru) 2009-10-30
UA80394C2 (en) 2007-09-25
JP2004518711A (ja) 2004-06-24
NO20033622L (no) 2003-10-06
HK1080361A1 (en) 2006-04-28
AR035750A1 (es) 2004-07-07
GB0119435D0 (en) 2001-10-03
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
CR7023A (es) 2003-11-17
US20050234105A1 (en) 2005-10-20
AP1749A (en) 2007-06-13
EA011319B1 (ru) 2009-02-27
TR200800691T2 (tr) 2008-03-21
NZ544720A (en) 2007-08-31
US7179821B2 (en) 2007-02-20
IL157341A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
PE20040175A1 (es) Metodo para tratar enfermedades o condiciones desmielinizantes
NO20024042D0 (no) Aryl-fusjonerte azapolysykliske forbindelser
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
PE107999A1 (es) Derivados 3-amidinoanilina, inhibidores del factor x de coagulacion de la sangre activado e intermediarios de los mismos
PE122899A1 (es) 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles sustituidos y procedimientos para su preparacion
EA199900689A1 (ru) Атропизомеры 3-гетероарил-4(3h)-хиназолинонов для лечения нейродегенеративных и связанных с травмами цнс состояний
EE9600142A (et) Helicobacter spp. vastased asoloonide derivaadid, nende valmistamise meetod ja kasutamine, vaheühendid, farmatseutiline kompositsioon ja selle valmistamise meetod ning terapeutiline kombinatsioon.
DK0804186T3 (da) Indolditerpenalkaloidforbindelser
DK0575429T3 (da) Behandlings af kognitive lidelser
RU2002132883A (ru) Новые полициклические инданилимидазолы, обладающие альфа2 адренергической активностью
ATE52776T1 (de) 1-phenyl-3-benzazepine.
ATE229328T1 (de) Venlafaxin und seine analoga zum herbeiführen einer verbesserung der kognitiven funktionen
ES2176513T3 (es) Empleo de 1-hidroxi-2-piridonas para el tratamiento de afecciones de las mucosas de dificil terapia.
ES2181387T3 (es) Derivados de azetidinocarboxamida para el tratamiento de trastornos del sistema nervioso central.
TW200503673A (en) Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
UY27206A1 (es) Método de tratamiento de condiciones o enfermedades desmielinizantes

Legal Events

Date Code Title Description
FC Refusal